Multiomics | Jotup

Global Orphan Drug Growth Opportunities Analysis - Reduced Exclusivity and Increased Competition will Drive Demand for More Efficient R&D and Digital Solutions - ResearchAndMarkets.com

Retrieved on:

Tuesday, April 2, 2024

The "Global Orphan Drug Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Global Orphan Drug Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
This study provides critical insights into the global orphan drug (OD) industry and highlights growth opportunities, revenue, regulatory changes, and technology trends influencing growth.
The growing number of unaddressed RD needs is a major catalyst for R&D.
There is a need for novel medicine to treat RDs that currently have limited therapeutic choices.

BD, Hamilton Collaborate to Standardize Single-Cell Multiomics Experiments Using Robotics

Retrieved on:

Tuesday, January 23, 2024

NGS, Library, Health, DNA, Multiomics, BDX, Single-cell analysis, Disease, Automation, Cell, Computer data storage

FRANKLIN LAKES, N.J., Jan. 23, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced a collaboration agreement with Hamilton, a leading global manufacturer of laboratory automation technology, to develop automated applications together with robotics-compatible reagent kits to enable greater standardization and reduced human error when conducting large-scale single-cell multiomics experiments.

Key Points:

The combination will automate steps, including pipetting and thermal cycling, to produce DNA samples or "libraries" that are ready for genetic sequencing.
In single-cell multiomics experiments, constructing libraries of fragmented genetic information that can be read by sequencing instruments is an essential first step before next-generation sequencing (NGS) can be performed and insights from cells can be gathered.
As more researchers adopt the rapidly evolving and important approach of single-cell multiomics, we believe that having automated solutions for high-throughput experiments will serve to accelerate their potentially life-changing discoveries."
The BD Rhapsody™ Single-Cell Analysis Library Preparation Reagent Kits and Hamilton Microlab® NGS STAR™ applications will be developed and released in phases starting in 2024.

EQS-News: Evotec announces CEO transition

Retrieved on:

Wednesday, January 3, 2024

Multiomics, Drug discovery, Friends, EVO, IPSC, Frankfurt Stock Exchange, MDAX, Overalls, Supervisory board, Just, Management

Werner Lanthaler will support a smooth and prompt transition of ongoing projects in the coming weeks.

Key Points:

Werner Lanthaler will support a smooth and prompt transition of ongoing projects in the coming weeks.
In the meantime, Dr Mario Polywka, currently Supervisory Board member and former COO of Evotec, agreed to serve as interim CEO.
The company sees itself on a strong path, especially based on its paradigm-shifting technologies, such as PanOmics, iPSC and Just – Evotec Biologics.
With PanOmics driven drug-discovery, iPSCs, and Just – Evotec Biologics the company is set up for long-term global leadership and success.

Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit

Retrieved on:

Tuesday, November 28, 2023

HEPA, NASH, Drug development, Multiomics, Conditional sentence, Doctor of Philosophy, Obesity, Artificial intelligence, AI, Fatty liver disease, Machine learning, Medical device

EDISON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it will present at the 7th Obesity & NASH Drug Development Summit taking place November 27 – 29, 2023 in Boston.

Key Points:

EDISON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it will present at the 7th Obesity & NASH Drug Development Summit taking place November 27 – 29, 2023 in Boston.
Scott Campbell, PhD, Hepion’s Quantitative Translational Pharmacologist, will deliver an oral presentation on the use of AI / machine learning (“ML”) to enrich NASH clinical trials and for NASH patient selection; and the use of multi-omics with ML for biomarker response prediction.
Using AI/ML and Multi-Omics to Determine Efficacy for Clinical NASH Study Enrichment: Highlights from Recently Completed Phase 2 Trials with Rencofilstat

EQS-News: Evotec presents precision medicine platforms for accelerated pipeline building at Capital Markets Day

Retrieved on:

Thursday, December 14, 2023

Therapy, Medicine, Capital market, A.I, MDAX, Frankfurt Stock Exchange, Disease, Just, Medication, EVO, Investment, ISIN, Multiomics, Creative industries

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today presents at its Capital Markets Day how the Company is driving more efficient pipeline building towards assets, that are progressing with higher probabilities of success.

Key Points:

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today presents at its Capital Markets Day how the Company is driving more efficient pipeline building towards assets, that are progressing with higher probabilities of success.
Evotec’s platforms leverage novel A.I.-powered technologies that lead to new opportunities, higher capital efficiency, and ultimately improved patient outcomes and commercial success.
Entitled “Shaping (new) markets”, the Capital Markets Day highlights Evotec’s advancements and key initiatives in precision medicine, PanOmics-driven drug discovery, iPSC-based disease modelling and cell therapy.
Pipeline building together with our partners is the most efficient way to improve probabilities of success and capital efficiency in biopharma research and development.”

Powered by Its Industry-Leading Comprehensive Multi-Omic Database, Caris Life Sciences to Showcase Research at ESMO 2023

Retrieved on:

Tuesday, October 17, 2023

IRVING, Texas, Oct. 17, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present seven studies across a breadth of tumor types at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain from October 20-24, 2023 (Booth #513). The findings demonstrate the power of Caris' comprehensive clinico-genomic database that enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.

Key Points:

The findings demonstrate the power of Caris' comprehensive clinico-genomic database that enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.
"The research being presented at this year's ESMO Congress is a testament to Caris' continued commitment to data-driven molecular innovation and large-scale collaboration to answer some of the pressing questions in precision oncology today," said Chadi Nabhan , M.D., MBA, FACP, Chairman of the Caris POA.
"The findings of these studies illustrate the power of comprehensive molecular profiling to identify underlying tumor biology setting the stage for therapeutics that improve patient outcomes.
Alongside our POA partners, we are pioneering new approaches to help deliver the right treatments to the right patients at the right time."

Psomagen Puts Spatial Biology and Multiomics in Focus, first CRO to launch 10X Genomics Xenium™ in situ Analyzer services in North America

Retrieved on:

Tuesday, September 12, 2023

Tissue, DNA, Genomics, CAP, Gene expression, RNA, Proteomics, Science, Multiomics, CLIA, Protein, Contract research organization, Developmental biology, Gene, Neurology, Microscope, Fine chemical, Rosenbergia xenium

ROCKVILLE, Md., Sept. 12, 2023 /PRNewswire/ -- Multiomics CRO Psomagen is thrilled to announce the launch of Spatial Biology services for 10X Genomics Xenium™.

Key Points:

ROCKVILLE, Md., Sept. 12, 2023 /PRNewswire/ -- Multiomics CRO Psomagen is thrilled to announce the launch of Spatial Biology services for 10X Genomics Xenium™.
According to Psomagen CEO Dr. Su Hong , "Psomagen's omics expertise makes us the perfect partner for North American customers."
Psomagen is a trusted Contract Research Organization (CRO) with nearly 20 years of genomics experience.
"Introducing spatial biology marks a pivotal moment in the evolution of Psomagen as a multiomics provider," stated Dr. Su Hong.

Baylor College of Medicine Human Genome Sequencing Center adopts Olink® Explore HT proteomics platform

Retrieved on:

Tuesday, August 8, 2023

Genetic variation, Biobank, UK Biobank, Molecule, Workflow, HT, NGS, Baylor University, Proteomics, Human genetics, Genetics, Protein, BCM, HGSC, Baylor College of Medicine, Gene, Multiomics, Disease, Medicine

UPPSALA, Sweden, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC) has selected the Olink Explore platform as a proteomics component of their world-class multiomics offering.

Key Points:

UPPSALA, Sweden, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC) has selected the Olink Explore platform as a proteomics component of their world-class multiomics offering.
“We are immensely pleased to see the Olink Explore HT platform implemented at one of the world’s leading multiomic research centers,“ said Jon Heimer, CEO, Olink Proteomics.
“Technology development and the adoption of new methods remains a priority at the HGSC, and we are excited to incorporate Olink’s technology into our portfolio,” said Richard Gibbs, Ph.D. Director, Human Genome Sequencing Center and Wofford Cain Professor of Molecular & Human Genetics, Baylor College of Medicine.
Olink Explore HT is the company's latest solution for high-throughput proteomics, delivering unmatched specificity, scalability, and simplicity.

Horse health research will help humans stay healthy, too, with insights on reining in diabetes and obesity

Retrieved on:

Tuesday, July 25, 2023

Both horses and people with endocrine disorders like Type 2 diabetes can suffer multiple types of musculoskeletal disorders.

Key Points:

Both horses and people with endocrine disorders like Type 2 diabetes can suffer multiple types of musculoskeletal disorders.
For example, horses with pituitary pars intermedia dysfunction – similar to Cushing’s disease in people – suffer from tendon and ligament degeneration.

Human and horse endocrine systems

Some endocrine disorders change how your body produces and releases hormones and can lead to osteoporosis, arthritis, ligament injury and other orthopedic diseases.
In fact, approximately 20% of horses and over 34% of people in the U.S. are affected by endocrine disorders such as metabolic syndrome.
For both species, the degree to which endocrine disorders are connected to obesity and its associated negative health effects is complex.
As mammals, horses and people share similar anatomy and endocrine physiology, and researchers have noted their parallel genetic links between obesity and metabolic disease.

Research to note

Because of the similarities between people and horses, research on diagnostics and treatments for metabolic conditions could provide health benefits to both species.
These drugs alter the kidneys’ ability to absorb sugar from urine such that the body eliminates some of the glucose it would normally absorb.
This greatly reduces blood insulin spikes, which can help prevent obesity, metabolic syndrome and cardiovascular disease in both horses and people.

Expanding precision medicine

Instead of the standard one-size-fits-all protocol, precision medicine uses information from a person’s genes, environment and medical history to create a customized treatment plan.
In horses, precision medicine currently focuses on DNA-based diagnostic tests to inform exercise regimens, treatment and breeding decisions.
Within precision medicine, doctors aim to get a full-picture view of an individual and their metabolic health by using multiomic analysis.

Quantiphi Named a Google Cloud Delivery Partner to Accelerate AI-Powered Innovations in Life Sciences

Retrieved on:

Monday, June 19, 2023

Cloud, Google Cloud Platform, Research, Drug design, Multiomics, Target, Organization, BigQuery, Medicine, Drug discovery, Artificial intelligence, AI, Health, Medical device, Sales, Pharmaceutical industry, Google Cloud

MARLBOROUGH, Mass, June 19, 2023 /PRNewswire-PRWeb/ -- Quantiphi, a leading AI-first digital engineering company, is proud to announce its inclusion as a strategic delivery partner in Google Cloud's recent launch of AI-powered solutions for drug discovery and precision medicine in the life sciences industry. Google Cloud's Target and Lead Identification suite and Multiomics Suite, featuring Quantiphi as a key delivery partner, aims to accelerate scientific breakthroughs and advance patient care.

Key Points:

Quantiphi announces its inclusion as a strategic delivery partner in Google Cloud's recent launch of AI-powered solutions for drug discovery and precision medicine in the life sciences industry.
Google Cloud's Target and Lead Identification suite and Multiomics Suite, featuring Quantiphi as a key delivery partner, aims to accelerate scientific breakthroughs and advance patient care.
As a delivery partner in Google Cloud's ecosystem, Quantiphi joins a select group of expert implementers for the Target and Lead Identification Suite and Multiomics Suite.
Quantiphi's collaboration with Google Cloud and expertise in data ingestion and analytics led to the company being featured as a Google Cloud delivery partner.